LEUKOCARE receives growth capital funding by LifeCare Partners and strengthens its board with industry experts

LEUKOCARE receives growth capital funding by LifeCare Partners and strengthens its board with industry experts

  • A group of investors led by LifeCare Partners have invested growth capital in LEUKOCARE.
  • In this context LEUKOCARE's supervisory board is strengthened by two new members Dr. Jean-Paul Prieels and Dr. Gerhard Ries.
  • Profound expertise and deep industry network will support LEUKOCARE's further development towards the leading provider for next generation formulation technologies.

Munich, Germany, 22 July 2015 - LEUKOCARE, a leading provider of stabilizing and protecting formulation technologies for proteins and other biologics, today announced the closing of its latest financing round providing growth capital to the company. The round was led by LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector, with participation from a group of new investors and current shareholders.

The financing will primarily be used to fund market access activities for a number of development projects based on LEUKOCARE's Stabilizing and Protecting Solutions (SPS®) in the fields of vaccines, biopharmaceuticals and combination devices.

"We believe that LEUKOCARE's SPS® formulation technology platform has the potential to bring a complete paradigm shift in improving thermal stability and shelf life of biological products and vaccines", says Dr. Gerhard Ries, Managing Partner at LifeCare Partners. "Unlike other formulation approaches, the SPS® technology facilitates a quantum leap in stabilizing biological molecules by offering even outstanding protection during sterilization of biopharmaceuticals and bio-functionalization of medical devices as well as avoiding cold chain logistics for vaccines".

As part of the financing, Dr. Gerhard Ries and Dr. Jean-Paul Prieels will join the supervisory board. Dr. Jean-Paul Prieels is a renowned industry expert in the vaccine field. He held various executive positions at GlaxoSmithKline, where he headed the vaccine research and development. "LEUKOCARE has developed an outstanding technology platform to develop exceptionally stable formulations for all kinds of biologics and particularly for vaccines", says Dr. Prieels. "I am deeply impressed by the potential of the SPS® technology platform and looking forward to support its further development as well as its roll out based on my network and my expertise in the field of vaccines."

"I am very proud to welcome the new investors as well as the new board members," states Michael Scholl, CEO with LEUKOCARE. "The fact that dedicated industry experts decided to support LEUKOCARE both with capital as well as substantial input is a validation of the path that we are successfully pursuing. It is a further essential step to assure our position as a reliable and competent provider of innovative formulation technologies to the industries of biopharmaceuticals, vaccines and combination devices."

 

- ENDS -

Notes To Editors

About LEUKOCARE

LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS®) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE's SPS® technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation and protect proteins in biologically functionalized combination devices.
LEUKOCARE is a privately owned biotechnology company founded in 2003, and headquartered in Martinsried/Munich, Germany. LEUKOCARE is currently involved in more than 15 collaborations with industrial partners.

Please visit: www.leukocare.com 

 

About LifeCare Partners

LifeCare Partners is an independent investment firm providing financing to private and public life science companies. LifeCare Partners targets the entire life science industry with special focus on medical technology, diagnostics, biopharmaceuticals, food & nutrition, industrial biotechnology, biomaterials, e-health and bioenergy. Based in Basel, the LifeCare Partners team has successfully invested in more than 30 life science companies over the last years, of which a large number have already been listed on the stock exchange or have been acquired by leading players in the life science industry.

Please visit: www.lifecarevc.com

 

Issued for and on behalf of LEUKOCARE by Instinctif Partners. 

For more information please contact:

Michael Scholl
CEO
Phone: +49 (0)89 780 16 65 – 0
Email: [email protected]

Instinctif Partners
Robert Mayer
T: +49-89-30905189-13
Email: [email protected]

 

 

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.